The biotech has been singled out for a $1.6bn payment for US Covid-19 vaccine development.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Five reasons why Astra should buy Gilead, and five why a move of this sort is pure fantasy.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.